Edward V Nunes1, Michael Gordon2, Peter D Friedmann3, Marc J Fishman4, Joshua D Lee5, Donna T Chen6, Mei Chen Hu7, Tamara Y Boney8, Donna Wilson9, Charles P O'Brien10. 1. New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States. Electronic address: nunesed@nyspi.columbia.edu. 2. Friends Research Institute, Inc. Baltimore, MD, United States. 3. Office of Research, Department of Medicine, University of Massachusetts - Baystate and Baystate Health, Springfield, MA, USA. 4. Friends Research Institute, Maryland Treatment Centers, Baltimore, MD, United States. 5. NYU School of Medicine, Department of Population Health, New York, NY, United States. 6. Center for Biomedical Ethics and Humanities and Department of Public Health Sciences, University of Virginia, Charlottesville, VA, United States. 7. Columbia University Medical Center, New York, NY, United States. 8. The University of Pennsylvania, CMCVAMC, Philadelphia, PA, United States. 9. Baystate Health, Springfield, MA, United States. 10. The University of Pennsylvania, Philadelphia, PA, United States.
Abstract
BACKGROUND: Opioid use disorder is often treated with short term hospitalization and medically supervised withdrawal from opioids followed by counseling alone without medication assisted treatment (MAT). More evidence is needed to confirm the expectation that the rate of relapse would be high after short term inpatient treatment and withdrawal from opioids without follow-up MAT. OBJECTIVE/ METHODS: To examine relapse to opioid use disorder in a randomized, multi-site effectiveness trial of extended-release injection naltrexone (XR-NTX) vs community-based treatment as usual (TAU) without medication, as a function of the type of clinical service where treatment was initiated-short-term inpatient (N=59), long-term inpatient (N=48), or outpatient (N=201). Inpatients typically were admitted to treatment actively using opioids and had completed withdrawal from opioids before study entry. Outpatients typically presented already abstinent for varying periods of time. RESULTS: One month after randomization, relapse rates on TAU by setting were: short-term inpatient: 63%; long term inpatient: 14%; outpatient: 28%. On XR-NTX relapse rates after one month were low (<12%) across all three settings. At the end of the 6 month trial, relapse rates on TAU were high across all treatment-initiation settings (short term inpatient 77%; long term inpatient 59%; outpatient 61%), while XR-NTX exerted a modest protective effect against relapse across settings (short term inpatient: 59%; long term inpatient 46%; outpatient 38%). CONCLUSIONS: Short term inpatient treatment is associated with a high rate of relapse among patients with opioid use disorder. These findings support the recommendation that medically supervised withdrawal from opioids should be followed by medication assisted treatment.
RCT Entities:
BACKGROUND: Opioid use disorder is often treated with short term hospitalization and medically supervised withdrawal from opioids followed by counseling alone without medication assisted treatment (MAT). More evidence is needed to confirm the expectation that the rate of relapse would be high after short term inpatient treatment and withdrawal from opioids without follow-up MAT. OBJECTIVE/ METHODS: To examine relapse to opioid use disorder in a randomized, multi-site effectiveness trial of extended-release injection naltrexone (XR-NTX) vs community-based treatment as usual (TAU) without medication, as a function of the type of clinical service where treatment was initiated-short-term inpatient (N=59), long-term inpatient (N=48), or outpatient (N=201). Inpatients typically were admitted to treatment actively using opioids and had completed withdrawal from opioids before study entry. Outpatients typically presented already abstinent for varying periods of time. RESULTS: One month after randomization, relapse rates on TAU by setting were: short-term inpatient: 63%; long term inpatient: 14%; outpatient: 28%. On XR-NTX relapse rates after one month were low (<12%) across all three settings. At the end of the 6 month trial, relapse rates on TAU were high across all treatment-initiation settings (short term inpatient 77%; long term inpatient 59%; outpatient 61%), while XR-NTX exerted a modest protective effect against relapse across settings (short term inpatient: 59%; long term inpatient 46%; outpatient 38%). CONCLUSIONS: Short term inpatient treatment is associated with a high rate of relapse among patients with opioid use disorder. These findings support the recommendation that medically supervised withdrawal from opioids should be followed by medication assisted treatment.
Authors: K M Carroll; S A Ball; C Nich; P G O'Connor; D A Eagan; T L Frankforter; E G Triffleman; J Shi; B J Rounsaville Journal: Arch Gen Psychiatry Date: 2001-08
Authors: Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling Journal: Arch Gen Psychiatry Date: 2011-11-07
Authors: Peter D Friedmann; Donna Wilson; Edward V Nunes; Randall Hoskinson; Joshua D Lee; Michael Gordon; Sean M Murphy; Richard J Bonnie; Donna T Chen; Tamara Y Boney; Charles P O'Brien Journal: J Subst Abuse Treat Date: 2017-02-22
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Darren R Christensen; Reid D Landes; Lisa Jackson; Lisa A Marsch; Michael J Mancino; Mohit P Chopra; Warren K Bickel Journal: J Consult Clin Psychol Date: 2014-08-04
Authors: Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson Journal: Am J Drug Alcohol Abuse Date: 2019-01-24 Impact factor: 3.829
Authors: Christopher A Blackwood; Michael Leary; Aaron Salisbury; Michael T McCoy; Jean Lud Cadet Journal: Neuroscience Date: 2019-07-24 Impact factor: 3.590
Authors: Matisyahu Shulman; Mei-Chen Hu; Maria A Sullivan; Sarah C Akerman; James Fratantonio; Vincent Barbieri; Edward V Nunes; Adam Bisaga Journal: Drug Alcohol Depend Date: 2022-02-02 Impact factor: 4.492
Authors: Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman Journal: Addiction Date: 2018-03-24 Impact factor: 6.526
Authors: Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen Journal: Lancet Date: 2017-11-14 Impact factor: 79.321
Authors: Maria A Sullivan; Adam Bisaga; Martina Pavlicova; Kenneth M Carpenter; C Jean Choi; Kaitlyn Mishlen; Frances R Levin; John J Mariani; Edward V Nunes Journal: Am J Psychiatry Date: 2018-10-19 Impact factor: 18.112
Authors: Ida Fredriksson; Sarah V Applebey; Angelica Minier-Toribio; Aniruddha Shekara; Jennifer M Bossert; Yavin Shaham Journal: Neuropsychopharmacology Date: 2020-01-06 Impact factor: 7.853
Authors: Lindsey R Hammerslag; Rebecca S Hofford; Qiwen Kang; Richard J Kryscio; Joshua S Beckmann; Michael T Bardo Journal: Drug Alcohol Depend Date: 2019-12-16 Impact factor: 4.492
Authors: Garrett James Jenkins; Michael J Cleveland; Kyler Scott Knapp; Scott C Bunce; H Harrington Cleveland Journal: Addict Behav Date: 2020-09-24 Impact factor: 3.913